QQ客服 官方微博 反馈留言

	Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial
	Park, Keunchil; Tan, Eng-Huat; O'Byrne, Ken; Zhang, Li; Boyer, Michael; Mok, Tony; Hirsh, Vera; Yang, James Chih-Hsin; Lee, Ki Hyeong; Lu, Shun
	2016
卷号	17期号:5页码:577-589
ISSN号	1470-2045
DOI	10.1016/S1470-2045(16)30033-X
URL标识	查看原文
收录类别	SCIE ; PUBMED ; ESI高被引论文 ; ESI热点论文
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/6383111
专题	中国医学科学院 北京协和医学院
推荐引用方式 GB/T 7714	Park, Keunchil,Tan, Eng-Huat,O'Byrne, Ken,et al. Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial[J],2016,17(5):577-589.
APA	Park, Keunchil.,Tan, Eng-Huat.,O'Byrne, Ken.,Zhang, Li.,Boyer, Michael.,...&Paz-Ares, Luis.(2016).Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.,17(5),577-589.
MLA	Park, Keunchil,et al."Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial".17.5(2016):577-589.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。